Press Release
Category Added in a WPeMatico Campaign
-
Long-term Follow-up Results of CARsgen’s Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
SHANGHAI, May 31, 2026 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR…
Read More » -
MICROIP to Debut “AI Vehicle System Business Group” and Edge AI Innovations at COMPUTEX 2026
TAIPEI, May 31, 2026 /PRNewswire/ — MICROIP (TPEx: 7796), specializing in AI software and ASIC design services, will unveil its “AI…
Read More » -
Carbice and Noctua Partner to Bring Advanced Thermal Pad Technology to DIY PC Builders
Noctua is the exclusive retail distributor of Carbice® IP90 thermal pads for the DIY PC market, beginning with the NT-CP1…
Read More » -
D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4 months in first-line KRAS G12C–mutant NSCLC (n=41) across…
Read More » -
AMD Bundles Carbice Ice Pad with Ryzen™ 7 5800X3D
The Carbice Ice Pad provides a reliable, peel-and-stick, maintenance-free thermal paste alternative designed for consistent gaming performance over the life of…
Read More » -
ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO
SUZHOU, China, May 31, 2026 /PRNewswire/ — ImmVira Group (“ImmVira”) today announced that preliminary Phase IIa clinical data for MVR-T3011,…
Read More » -
TiumBio to Present Phase 2a Interim Data Highlighting Differentiated Clinical Profile for Tosposertib(TU2218) plus Pembrolizumab in First-Line R/M HNSCC at ASCO 2026
75.0% Response Rate and Median PFS of 10.9 Months Observed in First-Line Recurrent or Metastatic Head and Neck Cancer(R/M HNSCC)…
Read More »